RGH-363

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameRGH-363
Drug Alias NameRGH-363
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D3 receptor antagonistsDopamine D2 receptor antagonists
TargetsDopamine D2 receptorDopamine D3 receptor
Therapy Area/IndicationsSchizophrenia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGedeon Richter
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGedeon Richter Plc
Active IndicationsN/A
Inactive IndicationsSchizophrenia

Other Information

ATC CodeN/A
Related LinksN/A